1、CRS Legal Sidebar Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i COVID-19 Medical Countermeasures: Intellectual Property and Affordability March 18, 2020 Federal agencies and private industry have begun efforts to develop and test medical countermeasures (such as antiv
2、iral treatments and vaccines) to combat COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. For example, Gilead Sciences has begun clinical trials, both in China and in the United States, to test whether its experimental antiviral drug remdesivir is safe and effective against COVID-19.
3、 In February 20202, the Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services (HHS), entered into agreements with two pharmaceutical companiesJohnson & Johnson and Sanofito develop vaccines for COVID-19. BARDA has also partnered wit
4、h Regeneron Pharmaceuticals to develop a monoclonal antibody treatment for COVID-19. (See this CRS report for further detail on these and other potential countermeasures against COVID-19.) Members of Congress have raised concerns about whether these medical countermeasures, if shown to be safe and e
升级VIP 